1
|
Miyazaki T, Aso Y, Goda Y. [Detection and Analysis of Drug Crystals in Medical Transdermal Patches by Using X-ray Diffraction Measurement]. YAKUGAKU ZASSHI 2021; 142:65-74. [PMID: 34645768 DOI: 10.1248/yakushi.21-00160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The crystallization of active pharmaceutical ingredients (APIs) in matrix-type transdermal patches has implications for the rate of drug absorption through the skin and patch adhesion strength. Therefore, the presence or absence and the degree of API crystallinity must be controlled to guarantee the quality of patches. In this study, the utility of laboratory-level X-ray diffractometers for the detection and analysis of crystalline APIs in transdermal patches was investigated using medical patches of tulobuterol and isosorbide dinitrate. Several matrix-type patches employ a controlled drug delivery system containing intentionally crystallized API. Both benchtop and high-resolution laboratory X-ray diffractometers can detect several characteristic peaks of the APIs in these patches even if the patches are wrapped in an outer bag, although a benchtop model provides peak heights one-seventh to one-fifth that of a high-resolution instrument. An isosorbide dinitrate patch containing an unintentionally crystallized spot was wrapped in an outer bag, followed by measurements using both X-ray diffractometers. For both instruments, several isosorbide dinitrate-derived peaks were detected only at the crystallized spot, although the signal-to-noise ratio was poorer for the benchtop model. These results show that a high-resolution X-ray diffractometer is advantageous for high-detection sensitivity and offers a high degree of freedom of the measurement position on the sample. It was concluded that a laboratory-level high-resolution X-ray diffractometer can be used to examine the crystalline state of APIs in patches inside an unopened outer bag.
Collapse
Affiliation(s)
| | - Yukio Aso
- National Institute of Health Sciences
| | | |
Collapse
|
2
|
Furuishi T, Kunimasu K, Fukushima K, Ogino T, Okamoto K, Yonemochi E, Tomono K, Suzuki T. Formulation design and evaluation of a transdermal drug delivery system containing a novel eptazocine salt with the Eudragit® E adhesive. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.101289] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
3
|
Del Río-Sancho S, Serna-Jiménez CE, Sebastián-Morelló M, Calatayud-Pascual MA, Balaguer-Fernández C, Femenía-Font A, Kalia YN, Merino V, López-Castellano A. Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport. Int J Pharm 2016; 517:104-111. [PMID: 27865983 DOI: 10.1016/j.ijpharm.2016.11.038] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Revised: 10/21/2016] [Accepted: 11/15/2016] [Indexed: 12/19/2022]
Abstract
Memantine is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of moderate to severe dementia including the symptoms of Alzheimer's disease (AD). It is administered orally but compliance, swallowing problems and the routine use of multiple medications in elderly AD patients means that an alternative route of administration would be of interest. The aim of the present study was to develop memantine hydrochloride occlusive transdermal therapeutic systems (TTS) for passive and iontophoretic delivery across the skin. Polyvinyl pyrrolidone (PVP) and a mixture with polyvinyl alcohol (PVA) were employed as polymeric matrices. The study involved the TTS characterization in addition to quantification of the memantine transport across porcine skin in vitro. The evaluation of the TTS physical properties suggested that systems were made more mechanically resistant by including PVA (6%) or high concentrations of PVP (24%). Moreover, a linear correlation was observed between the concentration of PVP and the bioadhesion of the systems. Drug delivery experiments showed that the highest transdermal flux provided by a passive TTS (PVP 24% w/w limonene) was 8.89±0.81μgcm-2h-1 whereas the highest iontophoretic transport was 46.4±3.6μgcm-2h-1. These innovative TTS would enable two dosage regimens that could lead to therapeutic plasma concentrations.
Collapse
Affiliation(s)
- S Del Río-Sancho
- Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Avenida Seminario s/n, 46113 Valencia, Spain; School of Pharmaceutical Sciences, University of Geneva & University of Lausanne, 1 Rue Michel-Servet, 1211 Geneva, Switzerland.
| | - C E Serna-Jiménez
- Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Avenida Seminario s/n, 46113 Valencia, Spain
| | - M Sebastián-Morelló
- Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Avenida Seminario s/n, 46113 Valencia, Spain
| | - M A Calatayud-Pascual
- Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Avenida Seminario s/n, 46113 Valencia, Spain
| | - C Balaguer-Fernández
- Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Avenida Seminario s/n, 46113 Valencia, Spain
| | - A Femenía-Font
- Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Avenida Seminario s/n, 46113 Valencia, Spain
| | - Y N Kalia
- School of Pharmaceutical Sciences, University of Geneva & University of Lausanne, 1 Rue Michel-Servet, 1211 Geneva, Switzerland
| | - V Merino
- Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM) Universitat Politecnica de València, Universitat de València, Departamento de Farmacia y Tecnología Farmacéutica y Parasitologia, Universidad de Valencia, Valencia, Spain
| | - A López-Castellano
- Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Avenida Seminario s/n, 46113 Valencia, Spain
| |
Collapse
|
4
|
Ita K. Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases. J Drug Target 2016; 25:406-419. [PMID: 27701893 DOI: 10.1080/1061186x.2016.1245310] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
With the increasing proportion of the global geriatric population, it becomes obvious that neurodegenerative diseases will become more widespread. From an epidemiological standpoint, it is necessary to develop new therapeutic agents for the management of Alzheimer's disease, Parkinson's disease, multiple sclerosis and other neurodegenerative disorders. An important approach in this regard involves the use of the transdermal route. With transdermal drug delivery systems (TDDS), it is possible to modulate the pharmacokinetic profiles of these medications and improve patient compliance. Transdermal drug delivery has also been shown to be useful for drugs with short half-life and low or unpredictable bioavailability. In this review, several transdermal drug delivery enhancement technologies are being discussed in relation to the delivery of medications used for the management of neurodegenerative disorders.
Collapse
Affiliation(s)
- Kevin Ita
- a College of Pharmacy, Touro University , Mare Island-Vallejo , CA , USA
| |
Collapse
|
5
|
Soler LI, Boix A, Lauroba J, Colom H, Domenech J. Transdermal delivery of alprazolam from a monolithic patch: formulation based on in vitro characterization. Drug Dev Ind Pharm 2011; 38:1171-8. [PMID: 22204649 DOI: 10.3109/03639045.2011.643893] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Alprazolam, a benzodiazepine widely used for the treatment of psychiatric disorders, has been aimed to be formulated in a transdermal delivery system (TDS) prototype. A series of TDS prototypes dosed in all cases at 0.35 mg·cm(-2) of alprazolam were prepared as a monolithic drug in adhesive matrix using acrylic pressure-sensitive adhesives (PSA) of acrylate vinyl acetate (Duro-tack(®)). The effects of several permeation enhancers as azone, transcutol, propylene glycol, dodecyl alcohol, decyl alcohol, diethanolamine, N-methyl pyrrolidone and lauric acid were studied. Prototypes have been characterized based on adhesion parameters (peel adhesion and shear adhesion), in vitro human skin permeation and in vitro drug release according to European Pharmacopoeia for the selected prototype. Best results show that a combination of permeation enhancers from different chemical groups is able to provide almost a 33 fold increase in the transdermal alprazolam flux of an aqueous saturated dispersion (from 0.054 ± 0.019 to 1.76 ± 0.21 μg h.cm(-2)). Based on these in vitro flux data, a predictive simulation of the achievable plasmatic levels was performed assuming a constant systemic infusion of drug. In summary, it is possible to obtain a prototype of a TDS of alprazolam with adequate adhesive properties (peel adhesion and shear adhesion) and able to predict sustained therapeutic plasmatic levels.
Collapse
Affiliation(s)
- L I Soler
- Biopharmacy and Pharmacokinetic group and Pharmaceutical Technology Department, School of Pharmacy, University of Barcelona, Spain.
| | | | | | | | | |
Collapse
|
6
|
Cilurzo F, Gennari CGM, Minghetti P. Adhesive properties: a critical issue in transdermal patch development. Expert Opin Drug Deliv 2011; 9:33-45. [PMID: 22171789 DOI: 10.1517/17425247.2012.637107] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Transdermal patches and medicated plasters (patch) represent well-established prolonged release dosage forms. Even if satisfactory adhesion to the skin is strictly linked to the efficacy and safety of the therapeutic treatment, nowadays numerous reports of in vivo 'adhesion lacking' are still addressed to regulatory agencies. The adhesive properties of a patch should be characterized considering i) the ability to form a bond with the surface of another material on brief contact and under light pressure (tack); ii) the resistance of the adhesive to flow (shear adhesion); and iii) the force required to peel away a patch from a surface (peel adhesion). AREAS COVERED In this manuscript, the most widely used methods to measure adhesive properties during development studies are described, along with the quality control of patches. The influence of formulative variables on patch adhesive properties, and their possible relationship with the in vivo adhesion performances, is also discussed. EXPERT OPINION The Pharmacopoeias should consider the opportunity of introducing compendial testing to assay the quality of adhesive patch properties, and regulatory agencies should issue proper guidelines to evaluate these features during development.
Collapse
Affiliation(s)
- Francesco Cilurzo
- Università degli Studi di Milano, Department of Pharmaceutical Science, Via G. Colombo, 71-20131, Milano, Italy.
| | | | | |
Collapse
|
7
|
Schulz M, Fussnegger B, Bodmeier R. Influence of adsorbents in transdermal matrix patches on the release and the physical state of ethinyl estradiol and levonorgestrel. Eur J Pharm Biopharm 2010; 77:240-8. [PMID: 21129483 DOI: 10.1016/j.ejpb.2010.11.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2010] [Revised: 11/04/2010] [Accepted: 11/12/2010] [Indexed: 11/17/2022]
Abstract
The drug release from medium molecular weight polyisobutene patches containing adsorbates (drug content: 0.2% ethinyl estradiol, 1.0% levonorgestrel; adsorbent content: 20%, w/w) increased in the order of no adsorbent<titanium dioxide<MCC<crospovidone. This was attributed to differences in drug crystallinity which increased in the order of crospovidone (crystal free)<MCC<titanium dioxide<no adsorbent and the water uptake which increased in the order of no adsorbent (0.1%)=titanium dioxide (0.1%)<MCC (1.6%)<crospovidone (4.8%) at 90% rh. Patches containing adsorbates onto crospovidone were investigated in detail. Increasing the adsorbate's drug loading increased the drug release up to a crospovidone content of 15% (w/w). Patches were crystal free for crospovidone contents ≥ 10% (w/w), which corresponds to a drug loading of crospovidone of 12% (w/w). In conclusion, the incorporation of drug adsorbates onto crospovidone into patches based on polyisobutene significantly increased the drug release (approximately 9.1 times for ethinyl estradiol and 15.4 times for levonorgestrel) and prevented drug recrystallization.
Collapse
Affiliation(s)
- Martin Schulz
- College of Pharmacy, Freie Universität Berlin, Berlin, Germany
| | | | | |
Collapse
|